Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.

Lee JM, Abraham L, Lam DL, Buist DSM, Kerlikowske K, Miglioretti DL, Houssami N, Lehman CD, Henderson LM, Hubbard RA.

J Clin Oncol. 2018 Jul 10;36(20):2070-2077. doi: 10.1200/JCO.2017.76.8267. Epub 2018 May 2.

PMID:
29718790
2.

Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers: A Case-Control Study.

Kerlikowske K, Scott CG, Mahmoudzadeh AP, Ma L, Winham S, Jensen MR, Wu FF, Malkov S, Pankratz VS, Cummings SR, Shepherd JA, Brandt KR, Miglioretti DL, Vachon CM.

Ann Intern Med. 2018 Jun 5;168(11):757-765. doi: 10.7326/M17-3008. Epub 2018 May 1.

PMID:
29710124
3.

Preoperative breast MRI and mortality in older women with breast cancer.

Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, Virnig BA, Henderson LM, Buist DSM, Wernli KJ, Kerlikowske K, Hubbard RA.

Breast Cancer Res Treat. 2018 Jul;170(1):149-157. doi: 10.1007/s10549-018-4732-z. Epub 2018 Mar 7.

PMID:
29516372
4.

Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.

Rice MS, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Norman AD, Visscher DW, Chen YY, Brandt KR, Couch FJ, Shepherd JA, Fan B, Wu FF, Ma L, Collins LC, Cummings SR, Kerlikowske K, Vachon CM.

Breast Cancer Res Treat. 2018 Jul;170(1):129-141. doi: 10.1007/s10549-018-4735-9. Epub 2018 Mar 3.

PMID:
29502324
5.

Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort.

Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):494-501. doi: 10.1001/jamainternmed.2017.8642.

PMID:
29435563
6.

Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer.

Buist DSM, Abraham L, Lee CI, Lee JM, Lehman C, O'Meara ES, Stout NK, Henderson LM, Hill D, Wernli KJ, Haas JS, Tosteson ANA, Kerlikowske K, Onega T; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):458-468. doi: 10.1001/jamainternmed.2017.8549.

PMID:
29435556
7.

Preoperative Breast Magnetic Resonance Imaging Use by Breast Density and Family History of Breast Cancer.

Henderson LM, Hubbard RA, Zhu W, Weiss J, Wernli KJ, Goodrich ME, Kerlikowske K, DeMartini W, Ozanne EM, Onega T.

J Womens Health (Larchmt). 2018 Jan 15. doi: 10.1089/jwh.2017.6428. [Epub ahead of print]

PMID:
29334616
8.

Utilization of breast cancer screening with magnetic resonance imaging in community practice.

Hill DA, Haas JS, Wellman R, Hubbard RA, Lee CI, Alford-Teaster J, Wernli KJ, Henderson LM, Stout NK, Tosteson ANA, Kerlikowske K, Onega T.

J Gen Intern Med. 2018 Mar;33(3):275-283. doi: 10.1007/s11606-017-4224-6. Epub 2017 Dec 6.

PMID:
29214373
9.

Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer.

Onega T, Weiss JE, Goodrich ME, Zhu W, DeMartini WB, Kerlikowske K, Ozanne E, Tosteson ANA, Henderson LM, Buist DSM, Wernli KJ, Herschorn SD, Hotaling E, O'Donoghue C, Hubbard R.

J Surg Oncol. 2017 Dec;116(8):1008-1015. doi: 10.1002/jso.24796. Epub 2017 Nov 11.

PMID:
29127715
10.

Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.

Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN.

Radiology. 2018 Mar;286(3):822-829. doi: 10.1148/radiol.2017170811. Epub 2017 Oct 25.

PMID:
29072981
11.

Emerging Trends in Family History of Breast Cancer and Associated Risk.

Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, Buist DSM, Egan KM, Newcomb PA, Trentham-Dietz A.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1753-1760. doi: 10.1158/1055-9965.EPI-17-0531. Epub 2017 Oct 6.

PMID:
28986348
12.

Combining quantitative and qualitative breast density measures to assess breast cancer risk.

Kerlikowske K, Ma L, Scott CG, Mahmoudzadeh AP, Jensen MR, Sprague BL, Henderson LM, Pankratz VS, Cummings SR, Miglioretti DL, Vachon CM, Shepherd JA.

Breast Cancer Res. 2017 Aug 22;19(1):97. doi: 10.1186/s13058-017-0887-5.

13.

Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.

Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR.

Breast Cancer Res Treat. 2017 Nov;166(2):603-612. doi: 10.1007/s10549-017-4430-2. Epub 2017 Aug 8.

PMID:
28791495
14.

Women's Awareness and Perceived Importance of the Harms and Benefits of Mammography Screening: Results From a 2016 National Survey.

Yu J, Nagler RH, Fowler EF, Kerlikowske K, Gollust SE.

JAMA Intern Med. 2017 Sep 1;177(9):1381-1382. doi: 10.1001/jamainternmed.2017.2247. No abstract available.

15.

Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.

Yaghjyan L, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Pankratz VS, Brandt K, Visscher D, Norman A, Couch F, Shepherd J, Fan B, Chen YY, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM.

Breast Cancer Res Treat. 2017 Sep;165(2):421-431. doi: 10.1007/s10549-017-4341-2. Epub 2017 Jun 17.

PMID:
28624977
16.

Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups.

Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS.

Cancer. 2017 Sep 15;123(18):3468-3475. doi: 10.1002/cncr.30756. Epub 2017 Jun 12.

17.

Performance Benchmarks for Screening Breast MR Imaging in Community Practice.

Lee JM, Ichikawa L, Valencia E, Miglioretti DL, Wernli K, Buist DSM, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD.

Radiology. 2017 Oct;285(1):44-52. doi: 10.1148/radiol.2017162033. Epub 2017 Jun 5.

PMID:
28582633
18.

Correlation Between Screening Mammography Interpretive Performance on a Test Set and Performance in Clinical Practice.

Miglioretti DL, Ichikawa L, Smith RA, Buist DSM, Carney PA, Geller B, Monsees B, Onega T, Rosenberg R, Sickles EA, Yankaskas BC, Kerlikowske K.

Acad Radiol. 2017 Oct;24(10):1256-1264. doi: 10.1016/j.acra.2017.03.016. Epub 2017 May 24.

PMID:
28551400
19.

National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium.

Sprague BL, Arao RF, Miglioretti DL, Henderson LM, Buist DS, Onega T, Rauscher GH, Lee JM, Tosteson AN, Kerlikowske K, Lehman CD; Breast Cancer Surveillance Consortium.

Radiology. 2017 Apr;283(1):59-69. doi: 10.1148/radiol.2017161519. Epub 2017 Feb 28.

20.

Supplemental Breast Cancer Screening: A Density Conundrum.

Tice JA, Kerlikowske K.

J Gen Intern Med. 2017 Jun;32(6):593-594. doi: 10.1007/s11606-017-3989-y. No abstract available.

21.

Women's experiences and preferences regarding breast imaging after completing breast cancer treatment.

Brandzel S, Rosenberg DE, Johnson D, Bush M, Kerlikowske K, Onega T, Henderson L, Nekhlyudov L, DeMartini W, Wernli KJ.

Patient Prefer Adherence. 2017 Feb 1;11:199-204. doi: 10.2147/PPA.S122244. eCollection 2017.

22.

Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer.

Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K; Breast Cancer Surveillance Consortium.

JAMA Oncol. 2017 Sep 1;3(9):1228-1236. doi: 10.1001/jamaoncol.2016.6326.

PMID:
28152151
23.

Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors.

Engmann NJ, Scott CG, Jensen MR, Ma L, Brandt KR, Mahmoudzadeh AP, Malkov S, Whaley DH, Hruska CB, Wu FF, Winham SJ, Miglioretti DL, Norman AD, Heine JJ, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):930-937. doi: 10.1158/1055-9965.EPI-16-0882. Epub 2017 Feb 1.

24.

Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.

Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K.

PLoS One. 2017 Jan 20;12(1):e0168601. doi: 10.1371/journal.pone.0168601. eCollection 2017.

25.

Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population.

Ahern TP, Sprague BL, Bissell MCS, Miglioretti DL, Buist DSM, Braithwaite D, Kerlikowske K.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):938-944. doi: 10.1158/1055-9965.EPI-16-0801. Epub 2017 Jan 17.

26.

Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.

Malkov S, Shepherd JA, Scott CG, Tamimi RM, Ma L, Bertrand KA, Couch F, Jensen MR, Mahmoudzadeh AP, Fan B, Norman A, Brandt KR, Pankratz VS, Vachon CM, Kerlikowske K.

Breast Cancer Res. 2017 Jan 4;19(1):1. doi: 10.1186/s13058-016-0797-y. No abstract available.

27.

Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.

Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL; Breast Cancer Surveillance Consortium.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw276. Print 2017 May.

28.

Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.

Malkov S, Shepherd JA, Scott CG, Tamimi RM, Ma L, Bertrand KA, Couch F, Jensen MR, Mahmoudzadeh AP, Fan B, Norman A, Brandt KR, Pankratz VS, Vachon CM, Kerlikowske K.

Breast Cancer Res. 2016 Dec 6;18(1):122. Erratum in: Breast Cancer Res. 2017 Jan 4;19(1):1.

29.

National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium.

Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DS, Kerlikowske K, Henderson LM, Onega T, Tosteson AN, Rauscher GH, Miglioretti DL.

Radiology. 2017 Apr;283(1):49-58. doi: 10.1148/radiol.2016161174. Epub 2016 Dec 5.

30.

Radiologist Agreement for Mammographic Recall by Case Difficulty and Finding Type.

Onega T, Smith M, Miglioretti DL, Carney PA, Geller BA, Kerlikowske K, Buist DS, Rosenberg RD, Smith RA, Sickles EA, Haneuse S, Anderson ML, Yankaskas B.

J Am Coll Radiol. 2016 Nov;13(11S):e72-e79. doi: 10.1016/j.jacr.2016.09.035.

PMID:
27814827
31.

Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy.

Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL.

JAMA Oncol. 2017 Jan 1;3(1):36-41. doi: 10.1001/jamaoncol.2016.3022.

32.

Breast cancer risk prediction using a clinical risk model and polygenic risk score.

Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E.

Breast Cancer Res Treat. 2016 Oct;159(3):513-25. doi: 10.1007/s10549-016-3953-2. Epub 2016 Aug 26.

33.

Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients.

Sherman ME, Ichikawa L, Pfeiffer RM, Miglioretti DL, Kerlikowske K, Tice J, Vacek PM, Gierach GL.

PLoS One. 2016 Aug 25;11(8):e0160966. doi: 10.1371/journal.pone.0160966. eCollection 2016.

34.

The Role of Preoperative Magnetic Resonance Imaging in the Assessment and Surgical Treatment of Interval and Screen-Detected Breast Cancer in Older Women.

Goodrich ME, Weiss J, Onega T, Balch SL, Buist DS, Kerlikowske K, Henderson LM, Hubbard RA; Breast Cancer Surveillance Consortium.

Breast J. 2016 Nov;22(6):616-622. doi: 10.1111/tbj.12651. Epub 2016 Aug 23.

35.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

36.

Locoregional treatment of breast cancer in women with and without preoperative magnetic resonance imaging.

Ozanne EM, Weiss JE, Onega T, DeMartini W, Kerlikowske K, Buist DS, Henderson L, Hubbard RA, Goodrich M, Tosteson AN, Virnig BA, O'Donoghue C.

Am J Surg. 2017 Jan;213(1):132-139.e2. doi: 10.1016/j.amjsurg.2016.03.014. Epub 2016 Jun 12.

37.

Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.

Molinaro AM, Sison JD, Ljung BM, Tlsty TD, Kerlikowske K.

Breast Cancer Res Treat. 2016 Jun;157(2):351-361. doi: 10.1007/s10549-016-3814-z. Epub 2016 May 4.

PMID:
27146587
38.

Breast Density: More Than Meets the Eye.

Kerlikowske K, Vachon CM.

J Natl Cancer Inst. 2016 Apr 29;108(10). pii: djw128. doi: 10.1093/jnci/djw128. Print 2016 Oct. No abstract available.

PMID:
27130894
39.

Breast MRI in the Diagnostic and Preoperative Workup Among Medicare Beneficiaries With Breast Cancer.

Onega T, Weiss JE, Buist DS, Tosteson AN, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, Wernli KJ, DeMartini WB, Virnig BA, Bennette CS, Hubbard RA.

Med Care. 2016 Jul;54(7):719-24. doi: 10.1097/MLR.0000000000000542.

40.

Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms--Reply.

Kerlikowske K.

JAMA Intern Med. 2016 Apr;176(4):562-3. doi: 10.1001/jamainternmed.2016.0225. No abstract available.

41.

Costs of diagnostic and preoperative workup with and without breast MRI in older women with a breast cancer diagnosis.

Onega T, Tosteson AN, Weiss J, Alford-Teaster J, Hubbard RA, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, Wernli KJ, DeMartini WB, Virnig BA.

BMC Health Serv Res. 2016 Feb 27;16:76. doi: 10.1186/s12913-016-1317-6.

42.

Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses.

Braithwaite D, Walter LC, Izano M, Kerlikowske K.

J Gen Intern Med. 2016 May;31(5):561-72. doi: 10.1007/s11606-015-3580-3. Epub 2016 Jan 29. Review.

43.

Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data.

Nelson HD, O'Meara ES, Kerlikowske K, Balch S, Miglioretti D.

Ann Intern Med. 2016 Feb 16;164(4):226-35. doi: 10.7326/M15-0971. Epub 2016 Jan 12.

44.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

45.

Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study.

Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, Kerlikowske K, Fenton JJ, Melnikow J, de Koning HJ, Hubbard RA.

Ann Intern Med. 2016 Feb 16;164(4):205-14. doi: 10.7326/M15-1241. Epub 2016 Jan 12.

46.

Comparison of Clinical and Automated Breast Density Measurements: Implications for Risk Prediction and Supplemental Screening.

Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP, Jensen MR, Whaley DH, Wu FF, Malkov S, Hruska CB, Norman AD, Heine J, Shepherd J, Pankratz VS, Kerlikowske K, Vachon CM.

Radiology. 2016 Jun;279(3):710-9. doi: 10.1148/radiol.2015151261. Epub 2015 Dec 22.

47.

Increased Risk of Developing Breast Cancer after a False-Positive Screening Mammogram.

Henderson LM, Hubbard RA, Sprague BL, Zhu W, Kerlikowske K.

Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1882-9. doi: 10.1158/1055-9965.EPI-15-0623.

48.

Factors Associated with Preoperative Magnetic Resonance Imaging Use among Medicare Beneficiaries with Nonmetastatic Breast Cancer.

Henderson LM, Weiss J, Hubbard RA, O'Donoghue C, DeMartini WB, Buist DS, Kerlikowske K, Goodrich M, Virnig B, Tosteson AN, Lehman CD, Onega T.

Breast J. 2016 Jan-Feb;22(1):24-34. doi: 10.1111/tbj.12522. Epub 2015 Oct 28.

49.

Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms.

Kerlikowske K.

JAMA Intern Med. 2015 Dec;175(12):1970-1. doi: 10.1001/jamainternmed.2015.6466. No abstract available.

50.

Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.

Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, Henderson LM, Smith RA; Breast Cancer Surveillance Consortium.

JAMA Oncol. 2015 Nov;1(8):1069-77. doi: 10.1001/jamaoncol.2015.3084.

Supplemental Content

Loading ...
Support Center